ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.40bn
- $2.44bn
- $1.07bn
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study
Acadia falls after Alzheimer's-related drug narrowly misses goal in study
Brief: Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results From Phase 2 Radiant Study Of Remlifanserin For The Treatment Of Alzheimer’S Disease Psychosis
Brief: ACADIA Pharmaceuticals - On Aug 24, Court Preliminarily Approves Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action - SEC Filing
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook
Brief: Acadia Pharmaceuticals Q2 EPS USD 0.18
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP
Acadia Pharmaceuticals Q1 revenue rises on DAYBUE growth